No profile data available.
Vericel Corporation (VCEL) is a healthcare company in the bone and joint treatment equipment industry, based in Burlington, United States, with about 398 full-time employees.
It reported revenue of $237.22 million for fiscal year 2024, up 20.1% from fiscal year 2023, and net income of $10.36 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $67.50 million, up 16.6% from a year before. Its market capitalization was $2.05 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Vericel reported $237.22 million in revenue for fiscal year 2024, up 20.1% from $197.52 million in fiscal year 2023. In Q3 2025 revenue was $67.50 million.
$2.05 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment equipment) include Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew plc (SNN), Globus Medical, Inc. (GMED), Alphatec Holdings, Inc. (ATEC).